Nextel Medical Corp. MAJI
Set alert
As of Nov 2, 12:22 PM ET
- YTD
- -94.55%
- 1 year
- -96.47%
- Open
- 0.003
- Prev close
- 0.0036
- Mkt cap
- 268.08K
- Vol
- 100.00K
- Avg vol
- 552.40K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.003
- High
- 0.003
News
3 weeks ago accessnewswire.com
NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals
Innovative Delivery Technologies Aimed at Enhancing Bioavailability and Expanding Patient Access Beyond Traditional Injections ORLANDO, FL / ACCESS Newswire / October 7, 2026 / NexTel Medical Corp.…
1 month ago accessnewswire.com
NexTel Medical Corp. Announces Strategic Joint Venture to Commercialize Breakthrough Patented Hair Regeneration Technology
Capitalizing on a Global Hair Restoration Market Projected to Exceed $23 Billion, the Venture Integrates Advanced Exosome Delivery to Eliminate Microneedling and Reactivate Follicles ORLANDO, FL /…
1 month ago accessnewswire.com
NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference
Company highlights ongoing clinical developments in traumatic brain injury (TBI) therapeutics and non-invasive cancer screening, sparking key vendor collaboration discussions. ORLANDO, FL / ACCESS…
2 months ago accessnewswire.com
NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussion
ORLANDO, FL / ACCESS Newswire / August 6, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI) ("NexTel" or the "Company") is issuing a clarification regarding statements made during an…
3 months ago accessnewswire.com
NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC
Strategic Acquisition Positions NexTel at the Forefront of Precision Neuro-Restoration with Xycota's Breakthrough Exosome-Delivered Brain Circuitry Repair Platform and Pending FDA Orphan Drug…
3 months ago accessnewswire.com
NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion Animals
Company targets a growing $1.2B+ North American pet oncology market leveraging proprietary exosome-based diagnostic technologies. ORLANDO, FL / ACCESS Newswire / July 28, 2026 / NexTel Medical Corp.…
3 months ago globenewswire.com
NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform
Revised transaction expands NexTel's acquisition from JumpstartRx and NuevistraMed to Island 40 Group's broader growth platform, adding health services, pharmaceutical access, lab testing,…
5 months ago globenewswire.com
NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization
NexTel Medical, OTCPK: MAJI, announced the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms
5 months ago globenewswire.com
NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist
ORLANDO, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery…
7 months ago globenewswire.com
Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced…
8 months ago globenewswire.com
Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions
ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to…
8 months ago globenewswire.com
Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition
ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCID: MAJI), a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, is pleased to…
10 months ago accessnewswire.com
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to…
11 months ago accessnewswire.com
Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement
ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company leveraging proprietary exosome-based delivery systems, today announced…
11 months ago accessnewswire.com
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
ORLANDO, FLORIDA / ACCESS Newswire / November 17, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced it…
12 months ago accessnewswire.com
Exousia Pro Announces Breakthrough In Exosome-Based Delivery
Successful loading of CBD material accelerates the path to revenue. ORLANDO, FL / ACCESS Newswire / November 4, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused…
1 year ago accessnewswire.com
Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage. ORLANDO, FLORIDA / ACCESS Newswire / October 28, 2025 / Exousia Pro, Inc. (formerly Marijuana, Inc.)…
1 year ago accessnewswire.com
Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes
ORLANDO, FLORIDA / ACCESS Newswire / September 29, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based therapies, today announced its…
1 year ago accessnewswire.com
Exousia Pro Reports Positive Outcome in Legal Proceeding
Focused on Protecting Shareholder Value and Advancing Core Business ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company…